Adeptus Health Inc Stock News

This month in March is a great time to pick up shares in these best penny stocks to buy. I chose the companies due to their strong fundamentals and potential for significant upside.

SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst

Adaptive Biotechnologies Corporation (ADPT) Q4 2023 Earnings Call Transcript

SEATTLE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst

SEATTLE, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst

Adaptive Biotechnologies offers services related to immunosequencing and immune medicine. Genius Sports' sports data and technology is used by more than 400 sports organizations worldwide.

SEATTLE, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst

Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Karina Calzadilla - Head, IR Chad Robins - CEO and Co-founder Tych

After a number of updates, there is no change in my investment rating for Adaptive Biotechnologies Corporation. Q2 FY'23 results showed mixed performance, with expectations for FY'23 sales to hit $215

Adaptive Biotechnologies (ADPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in t

SEATTLE, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the gen

Investing in biotech stocks is challenging even when you're investing in established companies with commercially available drugs and expansive pipelines. And investing in up-and-coming biotech stocks

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.33 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.37 per share a year ago.